Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy Purchases 88,850 Shares

Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy purchased 88,850 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was bought at an average price of $1.96 per share, with a total value of $174,146.00. Following the completion of the purchase, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This trade represents a 8.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Pyxis Oncology Stock Up 3.4 %

PYXS opened at $1.83 on Thursday. Pyxis Oncology, Inc. has a twelve month low of $1.48 and a twelve month high of $6.85. The company has a fifty day moving average of $3.54 and a 200-day moving average of $3.56. The stock has a market cap of $108.83 million, a PE ratio of -1.78 and a beta of 1.27.

Analysts Set New Price Targets

A number of research analysts recently commented on PYXS shares. Stifel Nicolaus assumed coverage on Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 price target for the company. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Stephens initiated coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 target price on the stock. Royal Bank of Canada upped their price target on shares of Pyxis Oncology from $7.00 to $10.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Institutional Trading of Pyxis Oncology

A number of large investors have recently bought and sold shares of the business. Ikarian Capital LLC acquired a new position in shares of Pyxis Oncology in the 1st quarter valued at about $7,082,000. Vanguard Group Inc. lifted its stake in Pyxis Oncology by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock valued at $5,970,000 after buying an additional 94,740 shares during the period. Millennium Management LLC boosted its holdings in shares of Pyxis Oncology by 125.3% during the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after buying an additional 743,499 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Pyxis Oncology by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after buying an additional 57,016 shares during the period. Finally, Blue Owl Capital Holdings LP acquired a new position in shares of Pyxis Oncology during the 2nd quarter valued at $3,462,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.